StockData
Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc. (KPTI) stock

KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTIQ
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 1/30
$0.04−0.01 (-20.00%)

Close on Nov 9, 2026Market cap $1.16KP/E –Yield –

Earnings

Karyopharm Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 2, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$33.40M
-11.9% on a year earlier
EPS, Q2 FY2026
-$2.32
-$4.32 a year earlier
Latest guidance
Raised
Aug 13, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Karyopharm Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 2, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 13, 2026before the open$33.40M-11.9%-$2.32Release
Q1 FY2026ended Mar 31, 2026May 14, 2026before the open$35.10M+17.0%-$1.24Release
Q4 FY2025ended Dec 31, 2025Feb 12, 2026before the open$34.10M+13.7%-$5.71Release
Q3 FY2025ended Sep 30, 2025Nov 3, 2025before the open$44.00M+13.4%-$3.82Release
Q2 FY2025ended Jun 30, 2025Aug 11, 2025before the open$37.90M-11.4%-$4.32Release
Q1 FY2025ended Mar 31, 2025May 12, 2025after the close$30.00M-9.4%-$2.77Release
Q4 FY2024ended Dec 31, 2024Jan 13, 2025before the open$30.00M-11.0%–Release
Q3 FY2024ended Sep 30, 2024Nov 5, 2024before the open$38.80M+7.8%-$0.26Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024before the open$42.80M+13.8%-$0.20Release
Q1 FY2024ended Mar 31, 2024May 8, 2024before the open$33.10M-14.5%-$0.32Release
Q4 FY2023ended Dec 31, 2023Feb 29, 2024before the open$33.70M-1.5%-$0.36Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Karyopharm Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total revenueFY2026$130.00M – $150.00M$130.00M – $150.00MRaisedAug 13, 2026
Total revenueFY2026$130.00M – $150.00M–NewFeb 12, 2026
R&D and selling, general and administrative (SG&A) expensesFY2026$230.00M – $245.00M$230.00M – $245.00MReaffirmedAug 13, 2026
R&D and selling, general and administrative (SG&A) expensesFY2026$230.00M – $245.00M–NewFeb 12, 2026

Guidance history

Every forecast Karyopharm Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 13, 2026R&D and selling, general and administrative (SG&A) expensesFY2026$230.00M – $245.00MReaffirmed
Aug 13, 2026Total revenueFY2026$130.00M – $150.00MRaised
Aug 13, 2026U.S. XPOVIO net product revenueFY2026$115.00M – $130.00MLowered
May 14, 2026R&D and selling, general and administrative (SG&A) expensesFY2026$230.00M – $245.00MNew
May 14, 2026Total revenueFY2026$130.00M – $150.00MNew
May 14, 2026U.S. XPOVIO net product revenueFY2026$115.00M – $130.00MLowered
Feb 12, 2026R&D and selling, general and administrative (SG&A) expensesFY2026$230.00M – $245.00MNew
Feb 12, 2026Total revenueFY2026$130.00M – $150.00MNew
Feb 12, 2026U.S. XPOVIO net product revenueFY2026$115.00M – $130.00MLowered
Nov 3, 2025U.S. XPOVIO net product revenueFY2025$110.00M – $120.00MLowered
Nov 3, 2025R&D and selling, general and administrative (SG&A) expensesFY2025$235.00M – $245.00MRaised
Nov 3, 2025Total revenueFY2025$140.00M – $155.00MRaised
Aug 11, 2025R&D and selling, general and administrative (SG&A) expensesFY2025$240.00M – $250.00MLowered
Aug 11, 2025Total revenueFY2025$140.00M – $155.00MRaised
Aug 11, 2025U.S. XPOVIO net product revenueFY2025$110.00M – $120.00MLowered
May 12, 2025R&D and selling, general and administrative (SG&A) expensesFY2025$240.00M – $255.00MNew
May 12, 2025Total revenueFY2025$140.00M – $155.00MNew
May 12, 2025U.S. XPOVIO net product revenueFY2025$115.00M – $130.00MLowered
Nov 5, 2024U.S. XPOVIO net product revenueFY2024$110.00M – $115.00MLowered
Nov 5, 2024R&D and selling, general and administrative (SG&A) expensesFY2024$255.00M – $265.00MRaised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Karyopharm Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Update
  3. Update
  4. Results
  5. Results
  6. Update
  7. Update
  8. Update
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Update
  15. Results

See a number that looks wrong?